Strensiq is a medicine used long-term to treat patients with hypophosphatasia that started in childhood. Hypophosphatasia is a rare inherited disease of the bones which can lead to early loss of teeth, malformed bones, frequent bone fractures, and difficulty breathing. Strensiq contains the active substance asfotase alfa. Hypophosphatasia is rare, and Strensiq was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 3 December 2008.
Therapeutic Indication
### Therapeutic indication Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
Therapeutic Area (MeSH)
ATC Code
A16AB
ATC Item
酶类
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| asfotase alfa | N/A | Asfotase alfa |
EMA Name
Strensiq
Medicine Name
Strensiq
Aliases
N/A
